Psychiatric side effects of interferon-β in multiple sclerosis

被引:64
作者
Goeb, JL
Even, C
Nicolas, G
Gohier, B
Dubas, F
Garré, JB
机构
[1] CHRU, Serv Psychiat Enfant Adolescent, F-59037 Lille, France
[2] Ctr Hosp St Anne, Clin Malad Mentales Encephale, Paris, France
[3] CHU Angers, Neurol Serv, Angers, France
[4] CHU Angers, Psychiat Serv, Angers, France
关键词
interferon; multiple sclerosis; side effects;
D O I
10.1016/j.eurpsy.2005.09.013
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Psychiatric disorders, especially depression, are frequent in patients with multiple sclerosis (MS). They are attributed both to the psychosocial impact of a chronic, usually progressive, disabling illness and to cerebral demyelination. Besides, drugs such as corticosteroids and possibly interferon (IFN) may also have depressogenic effects. Major depressive disorders and/or suicidal ideation are a major concern and efforts to identify and minimize these reactions are of much importance. Psychiatric side effects, particularly depression, are widely reported with IFN-alpha and have been suspected with IFN-beta but are not yet fully established. Our review of the literature revealed that most studies discard an association between IFN-beta and depression or suicide. However, few patients, especially those with a history of depression, might be at higher risk for depression when treated with IFN-beta. Overall, considering the uncertainty of a link between IFN-beta and depression and/or suicide, as well as the complete remission of psychiatric complications after IFN discontinuation and/or antidepressant treatment, physicians should closely monitor the psychiatric status of patients, but Should not refrain from including them in IFN-beta treatment programs, even when they have past or present depression. (c) 2005 Elsevier SAS. All rights reserved.
引用
收藏
页码:186 / 193
页数:8
相关论文
共 84 条
[71]   Psychiatric side effects of interferon therapy: prevalence, proposed mechanisms, and future directions [J].
Trask, PC ;
Esper, P ;
Riba, M ;
Redman, B .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (11) :2316-2326
[72]  
Valentine AD, 1998, SEMIN ONCOL, V25, P39
[73]  
van West Dirk, 1999, Neuro Endocrinol Lett, V20, P11
[74]  
VANTHIEL DH, 1995, EUR J GASTROEN HEPAT, V7, P165
[75]   Psychometric properties of the center for epidemiologic studies-depression scale in multiple sclerosis [J].
Verdier-Taillefer, MH ;
Gourlet, V ;
Fuhrer, R ;
Alpérovitch, A .
NEUROEPIDEMIOLOGY, 2001, 20 (04) :262-267
[76]   Interferon β1a (Avonex®) treatment in multiple sclerosis:: similarity of effect on progression of disability in patients with mild and moderate disability [J].
Vermersch, R ;
de Seze, J ;
Stojkovic, T ;
Hautecoeur, R .
JOURNAL OF NEUROLOGY, 2002, 249 (02) :184-187
[77]  
Walther EU, 1996, NERVENARZT, V67, P452
[78]  
Weiss K, 1998, SEMIN ONCOL, V25, P9
[79]   TUMOR NECROSIS FACTOR-ALPHA AND LIPOPOLYSACCHARIDE ENHANCE INTERFERON-INDUCED TRYPTOPHAN DEGRADATION AND PTERIDINE SYNTHESIS IN HUMAN-CELLS [J].
WERNERFELMAYER, G ;
WERNER, ER ;
FUCHS, D ;
HAUSEN, A ;
REIBNEGGER, G ;
WACHTER, H .
BIOLOGICAL CHEMISTRY HOPPE-SEYLER, 1989, 370 (09) :1063-1069
[80]  
Yong VW, 1998, NEUROLOGY, V51, P682